275 related articles for article (PubMed ID: 23944361)
1. Crosstalk between IGF-1R and other tumor promoting pathways.
Liu C; Zhang Z; Tang H; Jiang Z; You L; Liao Y
Curr Pharm Des; 2014; 20(17):2912-21. PubMed ID: 23944361
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors.
Obaid H; Kannappan S; Gupta M; Ruan Y; Zhang C; Bose P; Narendran A
Curr Cancer Drug Targets; 2020; 20(4):295-305. PubMed ID: 31713485
[TBL] [Abstract][Full Text] [Related]
3. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
[TBL] [Abstract][Full Text] [Related]
4. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effect of genistein on BG-1 ovarian cancer growth induced by 17 β-estradiol or bisphenol A via the suppression of the crosstalk between estrogen receptor α and insulin-like growth factor-1 receptor signaling pathways.
Hwang KA; Park MA; Kang NH; Yi BR; Hyun SH; Jeung EB; Choi KC
Toxicol Appl Pharmacol; 2013 Nov; 272(3):637-46. PubMed ID: 23933164
[TBL] [Abstract][Full Text] [Related]
6. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
Singh P; Alex JM; Bast F
Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor.
Davaadelger B; Duan L; Perez RE; Gitelis S; Maki CG
Oncotarget; 2016 May; 7(19):27511-26. PubMed ID: 27050276
[TBL] [Abstract][Full Text] [Related]
8. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer.
Buck E; Mulvihill M
Expert Opin Investig Drugs; 2011 May; 20(5):605-21. PubMed ID: 21446886
[TBL] [Abstract][Full Text] [Related]
11. Novel mechanisms of regulation of IGF-1R action: functional and therapeutic implications.
Worrall C; Nedelcu D; Serly J; Suleymanova N; Oprea I; Girnita A; Girnita L
Pediatr Endocrinol Rev; 2013 Jul; 10(4):473-84. PubMed ID: 23957198
[TBL] [Abstract][Full Text] [Related]
12. The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.
Matsunaga Y; Adachi Y; Sasaki Y; Koide H; Motoya M; Nosho K; Takagi H; Yamamoto H; Sasaki S; Arimura Y; Tokino T; Carbone DP; Imai K; Shinomura Y
Mol Carcinog; 2017 Feb; 56(2):515-526. PubMed ID: 27312358
[TBL] [Abstract][Full Text] [Related]
13. Recent advancements in small molecule inhibitors of insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase as anticancer agents.
Negi A; Ramarao P; Kumar R
Mini Rev Med Chem; 2013 Apr; 13(5):653-81. PubMed ID: 23373648
[TBL] [Abstract][Full Text] [Related]
14. Cell surface receptor expression patterns in osteosarcoma.
Hassan SE; Bekarev M; Kim MY; Lin J; Piperdi S; Gorlick R; Geller DS
Cancer; 2012 Feb; 118(3):740-9. PubMed ID: 21751203
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.
Hua H; Kong Q; Yin J; Zhang J; Jiang Y
J Hematol Oncol; 2020 Jun; 13(1):64. PubMed ID: 32493414
[TBL] [Abstract][Full Text] [Related]
16. The insulin-like growth factor 1 receptor in cancer: old focus, new future.
Hartog H; Wesseling J; Boezen HM; van der Graaf WT
Eur J Cancer; 2007 Sep; 43(13):1895-904. PubMed ID: 17624760
[TBL] [Abstract][Full Text] [Related]
17. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the insulin-like growth factor 1 receptor by CHM-1 blocks proliferation of glioblastoma multiforme cells.
Lin YC; Hou SC; Hung CM; Lin JN; Chen WC; Ho CT; Kuo SC; Way TD
Chem Biol Interact; 2015 Apr; 231():119-26. PubMed ID: 25643584
[TBL] [Abstract][Full Text] [Related]
19. [Stanozolol activates the cross-talk of estrogen receptor alpha-insulin-like growth factor-1 receptor-extracellular-signal regulated kinase 1/2 in the growth plate chondrocytes of estrogen-inhibited adolescent rats in vitro].
Zhu SY; Li YH; Ma HM; Pan SN; Chen HS; DU ML
Zhonghua Er Ke Za Zhi; 2009 Oct; 47(10):774-8. PubMed ID: 20021813
[TBL] [Abstract][Full Text] [Related]
20. Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer.
Singh I; Amin H; Rah B; Goswami A
Front Biosci (Schol Ed); 2013 Jan; 5(1):231-46. PubMed ID: 23277048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
